Cambridge gene therapy firm loses half of market cap on study results
Cambridge gene therapy firm Dimension Therapeutics on Tuesday announced disappointing results from a trial of its lead drug, cutting its market cap in half.
Dimension (Nasdaq: DMTX) announced preliminary data from a small Phase 1/2 study of a drug for hemophilia B, showing that while the treatment was somewhat effective in boosting a blood-clotting protein, some patients experienced liver toxicity.
The safety data appeared to raise serious concerns a mong investors. Shares of Dimension were down…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Max Stendahl Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Haemophilia | Health Management | Hemophilia | Liver | Study | Toxicology | Urology & Nephrology